Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

被引：0
|
作者：
Akira Yokomizo
Junji Yonese
Shin Egawa
Hiroshi Fukuhara
Hiroji Uemura
Kazuo Nishimura
Masayoshi Nagata
Atsushi Saito
Takumi Lee
Susumu Yamaguchi
Norio Nonomura
机构：
[1] Harasanshin Hospital,Department of Urology
[2] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Genitourinary Oncology
[3] Jikei University School of Medicine,Department of Urology
[4] Kyorin University School of Medicine,Department of Urology
[5] Yokohama City University Medical Center,Department of Urology and Renal Transplantation
[6] Osaka International Cancer Institute,Department of Urology
[7] Juntendo University Graduate School of Medicine,Department of Urology
[8] Astellas Pharma Inc.,Medical Affairs Japan
[9] Development,Department of Urology
[10] Astellas Pharma Inc.,undefined
[11] Osaka University Graduate School of Medicine,undefined
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Efficacy; Enzalutamide; Japan; Nonmetastatic castration-resistant prostate cancer; Real world; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：418 / 426
页数：8
相关论文
共 50 条
  • [1] Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
    Yokomizo, Akira
    Yonese, Junji
    Egawa, Shin
    Fukuhara, Hiroshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Nagata, Masayoshi
    Saito, Atsushi
    Lee, Takumi
    Yamaguchi, Susumu
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 418 - 426
  • [2] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
  • [3] Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer
    Hori, Akiyo
    Sahashi, Haruka
    Sano, Sora
    Matsumiya, Emiri
    Ariga, Maho
    Asano, Akari
    Soda, Midori
    Goto, Chitoshi
    Mizui, Takashi
    Komeda, Hisao
    Kitaichi, Kiyoyuki
    ANTICANCER RESEARCH, 2020, 40 (12) : 7101 - 7108
  • [4] Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
    Cattrini, Carlo
    Caffo, Orazio
    De Giorgi, Ugo
    Mennitto, Alessia
    Gennari, Alessandra
    Olmos, David
    Castro, Elena
    CANCERS, 2022, 14 (07)
  • [5] Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
    Roumiguie, Mathieu
    Paoletti, Xavier
    Neuzillet, Yann
    Mathieu, Romain
    Vincendeau, Sebastien
    Kleinclauss, Francois
    Mejean, Arnaud
    Guy, Laurent
    Timsit, Marc Olivier
    Lebret, Thierry
    FUTURE ONCOLOGY, 2021, 17 (14) : 1811 - 1823
  • [6] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [7] Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC
    Tohi, Yoichiro
    Kobayashi, Keita
    Daizumoto, Kei
    Sekino, Yohei
    Fukuhara, Hideo
    Niigawa, Heima
    Katayama, Satoshi
    Shimizu, Ryutaro
    Takamoto, Atsushi
    Nishimura, Kenichi
    Nagami, Taichi
    Hayashida, Yushi
    Hirama, Hiromi
    Shiraishi, Koji
    Tomida, Ryotaro
    Kobatake, Kohei
    Inoue, Keiji
    Miyaji, Yoshiyuki
    Bekku, Kensuke
    Morizane, Shuichi
    Miura, Noriyoshi
    Wada, Koichiro
    Sugimoto, Mikio
    Chu Shikoku Japan Urological Consortium, Keiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [8] Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2020, 16 (02): : 82 - 96
  • [9] Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Halabi, Susan
    Jiang, Shan
    Terasawa, Emi
    Garcia-Horton, Viviana
    Ayyagari, Rajeev
    Waldeck, A. Reginald
    Shore, Neal
    JOURNAL OF UROLOGY, 2021, 206 (02) : 298 - 307
  • [10] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13) : 1235 - 1246
12345